Answers are grounded in this paper and cite their sources.
Clinical commentary highlights potential underdiagnosis of dopamine-secreting tumors under current guidelines, suggesting routine methoxytyramine screening is needed.
Mustafa et al published an intriguing report on a “Dopamine-secreting carotid body paraganglioma (PGL) in a patient with an SDHB pathogenic variant.”1 In their discussion, they raise important clinical questions including whether dopamine-secreting PGLs are underdiagnosed due to a lack of adequate screening. Of note, the most recent Endocrine Society clinical guidelines, now outdated, do not recommend routine screening for dopamine or dopamine metabolites in patients with suspected pheochromocytoma or paragangliomas (PPGLs).
No takes yet. Share an insight, caveat, or question.
Sweeney et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: